BioSpace News Archive

Chiasma, Inc., a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, announced that it will host a conference call and live audio webcast on Thursday, May 7, 2020 at 5:00 p.m.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, reported financial results for the three months ended March 31, 2020.

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that it plans to host a conference call on Thursday, May 07, 2020, at 8:30 a.m. ET to discuss its first quarter financial results and recent operational highlights. Individuals may participate in the live call via telephone by dialin

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 8:30 a.m. EDT to report its financial results for the quarter ended March

Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, announced that Steve Salmon has joined its Board of Directors. Mr. Salmon will bring additional expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners, where he managed a number of portfolio comp

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has received Institutional Review Board (IRB) approval of its Phase 2 OPTION 2 clinical trial protocol to investigate MS1819 in cystic fibrosis (CF) patients with

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose. “These pre-clinical results confirm that all constructs are immunogeni

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of 2020. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 1470397. A live webcast of the presentation will be available on the Investors

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous sy

Progenity , a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the appointment of Troy Seelye as Chief Information Officer (CIO). Mr. Seelye will help to strengthen Progenity’s technology and data strategy, leading the development of key products and services designed to transform the customer experience. “Troy joins the Proge